Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24178875 | 0.75 | SIGMAR1 (0.46) | SIGMAR1MAOAACHE | |
| SCHEMBL19853699 | 0.75 | GRIN2B (0.54) | ACHE | |
| SCHEMBL8084099 | 0.74 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2 | |
| SCHEMBL24178962 | 0.74 | BCHE (0.46) | MAOACHRM2ACHE | |
| SCHEMBL31547204 | 0.71 | SIGMAR1 (0.88) | SIGMAR1MAOACHRM2 | |
| SCHEMBL7041148 | 0.70 | SIGMAR1 (0.58) | SIGMAR1MAOACHRM2 | |
| SCHEMBL23023030 | 0.69 | SIGMAR1 (0.52) | SIGMAR1MAOACHRM2 | |
| SCHEMBL22495345 | 0.69 | SIGMAR1 (0.63) | SIGMAR1MAOACHRM2 | |
| SCHEMBL19853711 | 0.69 | LMNA (0.36) | CHRM2 | |
| SCHEMBL4932707 | 0.68 | MAOA (0.95) | SIGMAR1MAOACHRM2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-20170051041-A1 | FACTOR VIII B CELL EPITOPE VARIANTS HAVING REDUCED IMMUNOGENICITY | BLOODWORKS | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SIGMAR1 115/4885MAOA 2003/4885CHRM2 572/4885 |
| US-20170051041-A1 | FACTOR VIII B CELL EPITOPE VARIANTS HAVING REDUCED IMMUNOGENICITY | F8, F13B, F13A1 | SIGMAR1 4717/4885MAOA 3235/4885CHRM2 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.